Eledon shares surge 10.15% intraday as updated islet cell transplant data show most patients achieve insulin independence with tegoprubart.

Eledon surged 10.15% intraday, driven by updated data from its islet cell transplantation study showing most patients achieved insulin independence after treatment with its lead candidate, tegoprubart.